Indian pharmaceutical firms are flocking to China, after the Asian giant opened its doors to generics and unveiled a raft of favorable regulatory reforms including accepting foreign clinical trial data to support new drug approvals.
More than half a dozen front-line Indian firms including Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd.,